An Open-Label, Multicenter, Phase Ib Study To Evaluate Safety, Pharmacokinetics, Pharmacodynamics, And Preliminary Anti-Tumor Activity Of RO7122290, A Fibroblast Activation Protein-A (FAP) Targeted 4-1BB Ligand (CD137L), In Combination With Cibisatamab With Obinutuzumab Pre-Treatment, In Participants With Previously Treated, Metastatic, Microsatellite-stable Colorectal Adenocarcinoma With High CEACAM5 Expression

This is an open-label, multicenter, Phase Ib study to determine the maximum tolerated dose (MTD) and/or the recommended Phase 2 dose (RP2D) in the weekly (QW) and/or every 3 weeks (Q3W) regimens, safety, tolerability, PK, immunogenicity, PD profile and to evaluate preliminary anti-tumor activity of RO7122290 in combination with cibisatamab Q3W after pretreatment with obinutuzumab, in participants with previously treated metastatic, microsatellite-stable colorectal adenocarcinoma with high CEACAM5 expression

开始日期2021-07-14

申办/合作机构

Hoffmann-La Roche, Inc.

NCT03866239

/ Terminated临床1期

A Phase Ib, Multicenter, Open-Label Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of Cibisatamab in Combination With Atezolizumab After Pretreatment With Obinutuzumab in Patients With Previously Treated Metastatic, Microsatellite-Stable Colorectal Adenocarcinoma With High CEACAM5 Expression

CO40939 is a Phase Ib, open-label, multicenter, single-arm study designed to evaluate the safety, efficacy, pharmacokinetics, and immunogenicity of cibisatamab in combination with atezolizumab administered after pretreatment with obinutuzumab in patients with Stage IV microsatellite stable (MSS) metastatic colorectal cancer (mCRC) whose tumors have high carcinoembryonic antigen-related cell adhesion molecule 5 (CEACAM5) expression and who have progressed on two or more chemotherapy regimens. The study is composed of a safety run-in and an exploratory part.

开始日期2019-05-07

申办/合作机构

Hoffmann-La Roche, Inc.

NCT03337698

/ Terminated临床1/2期

A Phase Ib/II, Open-Label, Multicenter, Randomized Umbrella Study Evaluating The Efficacy And Safety Of Multiple Immunotherapy-Based Treatment Combinations In Patients With Metastatic Non-Small Cell Lung Cancer (Morpheus-Lung)

This study will evaluate the efficacy, safety, and pharmacokinetics of immunotherapy-based treatment combinations in participants with metastatic non-small cell lung cancer (NSCLC).
Two cohorts will be enrolled in parallel in this study: Cohort 1 will consist of participants with tumor PD-L1 expression who have received no prior systemic therapy for metastatic NSCLC, and Cohort 2 will consist of participants who experienced disease progression during or following treatment with a platinum-containing regimen and a PD-L1/PD-1 checkpoint inhibitor, given in combination as one line of therapy or as two separate lines of therapy, regardless of PD-L1 expression. In each cohort, eligible participants will initially be assigned to one of several treatment arms (Stage 1). Participants who experience disease progression, loss of clinical benefit, or unacceptable toxicity during Stage 1 may be eligible to continue treatment with a different treatment regimen (Stage 2).

开始日期2017-12-27

申办/合作机构

Hoffmann-La Roche, Inc.

100 项与 Cibisatamab 相关的临床结果

登录后查看更多信息

100 项与 Cibisatamab 相关的转化医学

登录后查看更多信息

100 项与 Cibisatamab 相关的专利（医药）

登录后查看更多信息

项与 Cibisatamab 相关的文献（医药）

2023-11-01·CPT-Pharmacometrics & Systems Pharmacology

A model‐based approach leveraging in vitro data to support dose selection from the outset: A framework for bispecific antibodies in immuno‐oncology

Article

作者: Friberg, Lena E. ; Sánchez, Javier ; Gaillard, Brenda C. ; Marinho, Joana ; Frances, Nicolas ; Claus, Christina ; Jönsson, Siv ; Boehnke, Axel ; Albrecht, Rosmarie ; Tanos, Tamara ; McIntyre, Christine

Abstract:

FAP‐4‐1BBL is a bispecific antibody exerting 4‐1BB‐associated T‐cell activation only while simultaneously bound to the fibroblast activation protein (FAP) receptor, expressed on the surface of cancer‐associated fibroblasts. The trimeric complex formed when FAP‐4‐1BBL is simultaneously bound to FAP and 4‐1BB represents a promising mechanism to achieve tumor‐specific 4‐1BB stimulation. We integrated in vitro data with mathematical modeling to characterize the pharmacology of FAP‐4‐1BBL as a function of trimeric complex formation when combined with the T‐cell engager cibisatamab. This relationship was used to prospectively predict a range of clinical doses where trimeric complex formation is expected to be at its maximum. Depending on the dosing schedule and FAP‐4‐1BBL plasma: tumor distribution, doses between 2 and 145 mg could lead to maximum trimeric complex formation in the clinic. Due to the expected variability in both pharmacokinetic and FAP expression in the patient population, we predict that detecting a clear dose–response relationship would remain difficult without a large number of patients per dose level, highlighting that mathematical modeling techniques based on in vitro data could aid dose selection.

2022-01-01·Journal for immunotherapy of cancer2区 · 医学

JAK and mTOR inhibitors prevent cytokine release while retaining T cell bispecific antibody in vivo efficacy

2区 · 医学

ArticleOA

作者: Larivière, Laurent ; Freimoser-Grundschober, Anne ; Odermatt, Alex ; Umana, Pablo ; Stern, Martin ; Zimmermann, Tina ; Haegel, Hélène ; Leclercq, Gabrielle ; Giusti, Anna Maria ; Schneider, Anneliese ; Sam, Johannes ; Bacac, Marina ; Klein, Christian ; Green, Luke ; Challier, John ; Toso, Alberto ; Pulko, Vesna ; Steinhoff, Nathalie

Background:

T cell engaging therapies, like chimeric antigen receptor T cells and T cell bispecific antibodies (TCBs), efficiently redirect T cells towards tumor cells, facilitating the formation of a cytotoxic synapse and resulting in subsequent tumor cell killing, a process that is accompanied by the release of cytokines. Despite their promising efficacy in the clinic, treatment with TCBs is associated with a risk of cytokine release syndrome (CRS). The aim of this study was to identify small molecules able to mitigate cytokine release while retaining T cell-mediated tumor killing.

Methods:

By screening a library of 52 Food and Drug Administration approved kinase inhibitors for their impact on T cell proliferation and cytokine release after CD3 stimulation, we identified mTOR, JAK and Src kinases inhibitors as potential candidates to modulate TCB-mediated cytokine release at pharmacologically active doses. Using an in vitro model of target cell killing by human peripheral blood mononuclear cells, we assessed the effects of mTOR, JAK and Src kinase inhibitors combined with 2+1 T cell bispecific antibodies (TCBs) including CEA-TCB and CD19-TCB on T cell activation, proliferation and target cell killing measured by flow cytometry and cytokine release measured by Luminex. The combination of mTOR, JAK and Src kinase inhibitors together with CD19-TCB was evaluated in vivo in non-tumor bearing stem cell humanized NSG mice in terms of B cell depletion and in a lymphoma patient-derived xenograft (PDX) model in humanized NSG mice in terms of antitumor efficacy.

Results:

The effect of Src inhibitors differed from those of mTOR and JAK inhibitors with the suppression of CD19-TCB-induced tumor cell lysis in vitro, whereas mTOR and JAK inhibitors primarily affected TCB-mediated cytokine release. Importantly, we confirmed in vivo that Src, JAK and mTOR inhibitors strongly reduced CD19-TCB-induced cytokine release. In humanized NSG mice, continuous treatment with a Src inhibitor prevented CD19-TCB-mediated B cell depletion in contrast to mTOR and JAK inhibitors, which retained CD19-TCB efficacy. Ultimately, transient treatment with Src, mTOR and JAK inhibitors minimally interfered with antitumor efficacy in a lymphoma PDX model.

Conclusions:

Taken together, these data support further evaluation of the use of Src, JAK and mTOR inhibitors as prophylactic treatment to prevent occurrence of CRS.

2022-01-01·Theranostics1区 · 医学

Three-dimensional colon cancer organoids model the response to CEA-CD3 T-cell engagers

1区 · 医学

ArticleOA

作者: Garasa, Saray ; Cirella, Asunta ; Olivera, Irene ; Teijeira, Alvaro ; Alvarez, Maite ; Ochoa, Maria C ; Klein, Christian ; Ponz, Mariano ; Cañamero, Marta ; Bacac, Marina ; Rodriguez-Ruiz, Maria E ; Luri, Carlos ; Sanmamed, Miguel F ; Migueliz, Itziar ; Melero, Ignacio ; Rouzaut, Ana ; Umaña, Pablo ; Karanikas, Vaios

Rationale: The CEA-CD3 T cell bispecific antibody cibisatamab (CEA-TCB) is currently undergoing clinical trials. Here we study its performance against three-dimensional tumor organoids in cocultures with T cells as compared to a higher affinity CEACAM5-CD3 (CEACAM5-TCB) bispecific antibody using time-lapse confocal microscopy. Methods: Pre-labelled spheroids derived from colon cancer cell lines and primary organoids derived from four colorectal cancer surgical specimens, which expressed different graded levels of CEA, were exposed in cocultures to T lymphocytes. Cocultures were treated with CEA-CD3 T-cell engagers and were followed by live confocal microscopy. Caspase 3 activation detected in real-time was used as an indicator of tumor cell death. Co-cultures were also set up with autologous tumor-associated fibroblasts to test the co-stimulatory effect of a fibroblast activated protein (FAP)- targeted 4-1BBL bispecific antibody fusion protein currently undergoing clinical trials. Results: Tumor-cell killing of 3D colon carcinoma cultures was dependent on the levels of surface CEA expression, in such a way that the lower affinity agent (CEA-TCB) did not mediate killing by human preactivated T cells below a certain CEA expression threshold, while the high affinity construct (CEACAM5-TCB) remained active on the low CEA expressing organoids. Modelling heterogeneity in the levels of CEA expression by coculturing CEA high and low organoids showed measurable but weak bystander killing. Cocultures of tumor organoids, autologous fibroblasts and T cells allowed to observe a costimulatory effect of anti-FAP-4-1BBL both to release IFNγ and to attain more efficacious tumor cell killing. Conclusion: Three-dimensional tumor cocultures with T cells using live confocal microscopy provide suitable models to test the requirements for colon-cancer redirected killing as elicited by CEA-targeted T-cell engagers undergoing clinical trials and treatment allow combinations to be tested in a relevant preclinical system.

项与 Cibisatamab 相关的新闻（医药）

2026-06-29

·泰克赛思Oncology Research

Oncology Research Vol.34, No.7, 2026 | 从AI赋能到精准治疗：13篇前沿综述勾勒肿瘤研究新图景

癌症研究正在经历一场深刻变革。从人工智能驱动的精准诊疗，到新型抗体药物、纳米递药系统、天然活性分子和免疫代谢重编程等前沿方向，基础研究与临床转化之间的距离正在不断缩短。面对肿瘤异质性、耐药性和治疗反应差异等长期挑战，研究者们正尝试从分子机制、肿瘤微环境、药物工程、生物标志物以及数字医学等多个维度寻找突破口。本期Oncology Research第34卷第7期共收录13篇综述，涵盖乳腺癌、肺癌、肝癌、胰腺癌、胃肠道肿瘤、骨肿瘤及霍奇金淋巴瘤等多个研究领域，同时聚焦ADC药物、双特异性抗体、人工智能、天然肽、白藜芦醇、纳米载体及组织非特异性精准治疗等热点方向。无论是基础转化研究还是临床治疗优化，本辑文章均提供了系统而深刻的见解。精选导读 A New Paradigm of Bispecific Antibodies in Clinical Management of Gastrointestinal Cancers 双特异性抗体开启胃肠道肿瘤治疗新范式 Huimin Zhao, Xiuran Wang, Zhimeng Fan, Ai Sun, Changhua Zhang, Chunhui Sun Graphic Abstract 面对胃肠道肿瘤复杂的免疫抑制微环境，传统单靶点治疗常常难以获得理想疗效。本文全面综述了双特异性抗体在结直肠癌、胃癌、胰腺癌、胆道癌、食管癌和肝癌中的研究进展，重点介绍了CEA-TCB、RG7802等代表性药物以及其通过同时连接肿瘤抗原和免疫细胞增强抗肿瘤免疫的机制。文章还分析了细胞因子释放综合征、脱靶毒性和肿瘤异质性等挑战，并讨论了人工智能辅助靶点发现和结构优化在未来药物开发中的应用前景。引用格式： APA Style Zhao, H., Wang, X., Fan, Z., Sun, A., Zhang, C. et al. (2026). A New Paradigm of Bispecific Antibodies in Clinical Management of Gastrointestinal Cancers. Oncology Research, 34(7), 7. https://doi.org/10.32604/or.2026.078825 Vancouver Style Zhao H, Wang X, Fan Z, Sun A, Zhang C, Sun C. A New Paradigm of Bispecific Antibodies in Clinical Management of Gastrointestinal Cancers. Oncol Res. 2026;34(7):7. https://doi.org/10.32604/or.2026.078825 IEEE Style H. Zhao, X. Wang, Z. Fan, A. Sun, C. Zhang, and C. Sun, “A New Paradigm of Bispecific Antibodies in Clinical Management of Gastrointestinal Cancers,” Oncol. Res., vol. 34, no. 7, pp. 7, 2026. https://doi.org/10.32604/or.2026.078825 长按识别二维码阅读英文全文 01 Tissue-Agnostic Targeting in Solid Tumors: A PRISMA-Compliant Meta-Analysis of Efficacy, Safety, and Resistance Determinants Across Histologies 实体瘤组织非特异性靶向治疗：疗效、安全性与耐药机制的Meta分析 Marwa Balaha, Saad A. Aldosari, Ahmed A. Alamer, Nehad Ahmed, Mohamed F. Balaha Graphic Abstract 随着精准肿瘤学的发展，“同一分子异常、不同组织来源”的治疗理念正逐渐成为现实。本文基于PRISMA规范，对38项研究、超过15000例患者的数据进行了系统评价和Meta分析，评估了HER2、MSI-H/dMMR以及BRAF V600E等生物标志物指导下的组织非特异性治疗效果。结果显示，曲妥珠单抗德鲁替康、PD-1抑制剂和恩考拉非尼等精准治疗方案能够显著改善患者生存获益。作者同时分析了不同治疗策略的毒性特点及耐药因素，强调标准化检测和生物标志物验证对于推动组织非特异性治疗广泛应用的重要意义。引用格式： APA Style Balaha, M., Aldosari, S.A., Alamer, A.A., Ahmed, N., Balaha, M.F. (2026). Tissue-Agnostic Targeting in Solid Tumors: A PRISMA-Compliant Meta-Analysis of Efficacy, Safety, and Resistance Determinants Across Histologies. Oncology Research, 34(7), 5. https://doi.org/10.32604/or.2026.077965 Vancouver Style Balaha M, Aldosari SA, Alamer AA, Ahmed N, Balaha MF. Tissue-Agnostic Targeting in Solid Tumors: A PRISMA-Compliant Meta-Analysis of Efficacy, Safety, and Resistance Determinants Across Histologies. Oncol Res. 2026;34(7):5. https://doi.org/10.32604/or.2026.077965 IEEE Style M. Balaha, S. A. Aldosari, A. A. Alamer, N. Ahmed, and M. F. Balaha, “Tissue-Agnostic Targeting in Solid Tumors: A PRISMA-Compliant Meta-Analysis of Efficacy, Safety, and Resistance Determinants Across Histologies,” Oncol. Res., vol. 34, no. 7, pp. 5, 2026. https://doi.org/10.32604/or.2026.077965 长按识别二维码阅读英文全文 02 Emerging Approaches in Breast Cancer: From Molecular Mechanisms to Diagnosis and Therapeutic Strategies 乳腺癌的新兴研究路径：从分子机制到诊断与治疗策略 Raquel Sanchez-Baltasar, Nerea Castañeda-Fernández, Jorge Olivares-Arancibia, Carlos Torres-Villar, Julio Plaza-Diaz, Lourdes Herrera-Quintana 乳腺癌诊断的新方法随着精准医学时代的到来，乳腺癌的诊疗模式正在从传统病理分类向分子分型和个体化管理转变。本文系统梳理了乳腺癌的分子发病机制以及近年来在诊断技术和治疗策略方面的重要进展，通过综合分析液体活检、多组学分子谱分析、人工智能辅助诊断以及HER2靶向治疗、DNA损伤修复靶向药物和细胞周期调控药物等前沿领域的研究成果，探讨了肿瘤异质性、耐药机制及医疗公平性等现实挑战。作者认为，未来多技术融合的平台有望显著提升乳腺癌早期诊断准确率和治疗效果，但其临床价值仍需标准化验证和广泛推广。引用格式： APA Style Sanchez-Baltasar, R., Castañeda-Fernández, N., Olivares-Arancibia, J., Torres-Villar, C., Plaza-Diaz, J. et al. (2026). Emerging Approaches in Breast Cancer: From Molecular Mechanisms to Diagnosis and Therapeutic Strategies. Oncology Research, 34(7), 1. https://doi.org/10.32604/or.2026.081924 Vancouver Style Sanchez-Baltasar R, Castañeda-Fernández N, Olivares-Arancibia J, Torres-Villar C, Plaza-Diaz J, Herrera-Quintana L. Emerging Approaches in Breast Cancer: From Molecular Mechanisms to Diagnosis and Therapeutic Strategies. Oncol Res. 2026;34(7):1. https://doi.org/10.32604/or.2026.081924 IEEE Style R. Sanchez-Baltasar, N. Castañeda-Fernández, J. Olivares-Arancibia, C. Torres-Villar, J. Plaza-Diaz, and L. Herrera-Quintana, “Emerging Approaches in Breast Cancer: From Molecular Mechanisms to Diagnosis and Therapeutic Strategies,” Oncol. Res., vol. 34, no. 7, pp. 1, 2026. https://doi.org/10.32604/or.2026.081924 长按识别二维码阅读英文全文 03 Preclinical Models of Colorectal Cancer Liver Metastasis: Therapeutic Evaluation and Translational Implications 结直肠癌肝转移前临床模型：治疗评价与转化研究意义 Ye Ri Han, Sang Bong Lee 结直肠癌肝转移（CRLM）的临床前建模和治疗策略的综合景观尽管针对结直肠癌肝转移的治疗手段不断丰富，但大量前临床成果仍难以成功转化为临床获益。本文聚焦不同类型的结直肠癌肝转移动物模型，系统评估了原位模型、转移模型以及新型生物材料辅助模型在模拟肝脏微环境、免疫调控和药物反应方面的表现。通过对现有实验平台优势与不足的比较分析，作者提出合理选择研究模型对于提高药物开发成功率和临床转化效率具有关键意义。引用格式： APA Style Han, Y.R., Lee, S.B. (2026). Preclinical Models of Colorectal Cancer Liver Metastasis: Therapeutic Evaluation and Translational Implications. Oncology Research, 34(7), 8. https://doi.org/10.32604/or.2026.079556 Vancouver Style Han YR, Lee SB. Preclinical Models of Colorectal Cancer Liver Metastasis: Therapeutic Evaluation and Translational Implications. Oncol Res. 2026;34(7):8. https://doi.org/10.32604/or.2026.079556 IEEE Style Y. R. Han and S. B. Lee, “Preclinical Models of Colorectal Cancer Liver Metastasis: Therapeutic Evaluation and Translational Implications,” Oncol. Res., vol. 34, no. 7, pp. 8, 2026. https://doi.org/10.32604/or.2026.079556 长按识别二维码阅读英文全文 04 Clostridiaceae in Cancer Management 梭菌科细菌在癌症治疗中的应用前景 Julia Banaszkiewicz, Paweł Krawczyk, Tomasz Grenda, Anna Grenda 应用梭菌属细菌进行抗癌治疗长期以来，肿瘤缺氧区域一直是传统治疗难以有效覆盖的“盲区”。本文聚焦梭菌科细菌在癌症治疗中的创新应用，系统总结了包括Clostridium novyi-NT在内的多种厌氧菌株如何选择性定植于肿瘤缺氧区域并发挥抗肿瘤作用。通过分析细菌介导的细胞裂解、免疫激活以及基因工程改造后促进前药激活等机制，作者指出细菌疗法与放疗、化疗及免疫治疗联合应用能够产生显著协同效应，为实体瘤治疗提供全新的生物治疗策略。引用格式： APA Style Banaszkiewicz, J., Krawczyk, P., Grenda, T., Grenda, A. (2026). Clostridiaceae in Cancer Management. Oncology Research, 34(7), 4. https://doi.org/10.32604/or.2026.074037 Vancouver Style Banaszkiewicz J, Krawczyk P, Grenda T, Grenda A. Clostridiaceae in Cancer Management. Oncol Res. 2026;34(7):4. https://doi.org/10.32604/or.2026.074037 IEEE Style J. Banaszkiewicz, P. Krawczyk, T. Grenda, and A. Grenda, “Clostridiaceae in Cancer Management,” Oncol. Res., vol. 34, no. 7, pp. 4, 2026. https://doi.org/10.32604/or.2026.074037 长按识别二维码阅读英文全文 05 Monoclonal Antibodies and Derivatives: Therapeutic Tools for Cancer 单克隆抗体及其衍生物：癌症治疗的重要武器 Alessandro Poggi 用肿瘤细胞的单克隆抗体及其衍生物靶向肿瘤细胞从鼠源单抗到全人源抗体，抗体药物的发展历程几乎贯穿了现代肿瘤免疫治疗的发展史。本文系统回顾了单克隆抗体及其衍生技术的发展演变，重点介绍了ADC、双特异性抗体、CAR-T细胞疗法以及抗HER2、PD-1/PD-L1等经典治疗策略的作用机制和临床应用。作者还探讨了分子胶降解剂偶联抗体以及Affibody等新兴技术平台的潜力，认为未来抗体药物将进一步突破“不可成药靶点”的限制，推动精准治疗迈向新阶段。引用格式： APA Style Poggi, A. (2026). Monoclonal Antibodies and Derivatives: Therapeutic Tools for Cancer. Oncology Research, 34(7), 6. https://doi.org/10.32604/or.2026.078483 Vancouver Style Poggi A. Monoclonal Antibodies and Derivatives: Therapeutic Tools for Cancer. Oncol Res. 2026;34(7):6. https://doi.org/10.32604/or.2026.078483 IEEE Style A. Poggi, “Monoclonal Antibodies and Derivatives: Therapeutic Tools for Cancer,” Oncol. Res., vol. 34, no. 7, pp. 6, 2026. https://doi.org/10.32604/or.2026.078483 长按识别二维码阅读英文全文 06 Emerging Nanocarrier Strategies for Optimized Drug Delivery in the Treatment of Primary Bone Cancer 原发性骨癌治疗中的新型纳米载体递药策略 Lindokuhle M. Ngema, Samson A. Adeyemi, Yahya E. Choonara 为骨癌靶向药物递送而设计的典型纳米载体的图形表示如何提高药物在肿瘤组织中的精准富集，一直是骨肿瘤治疗领域的重要课题。本文围绕骨肉瘤、软骨肉瘤和尤文肉瘤三类主要原发性骨癌，系统总结了纳米递药系统在改善药物生物利用度、增强肿瘤靶向性以及克服耐药性方面的研究进展。作者通过梳理不同类型纳米载体的设计理念和应用成果，指出纳米医学有望显著优化传统化疗效果，并为未来骨癌精准治疗提供新的解决方案。引用格式： APA Style Ngema, L.M., Adeyemi, S.A., Choonara, Y.E. (2026). Emerging Nanocarrier Strategies for Optimized Drug Delivery in the Treatment of Primary Bone Cancer. Oncology Research, 34(7), 9. https://doi.org/10.32604/or.2026.077723 Vancouver Style Ngema LM, Adeyemi SA, Choonara YE. Emerging Nanocarrier Strategies for Optimized Drug Delivery in the Treatment of Primary Bone Cancer. Oncol Res. 2026;34(7):9. https://doi.org/10.32604/or.2026.077723 IEEE Style L. M. Ngema, S. A. Adeyemi, and Y. E. Choonara, “Emerging Nanocarrier Strategies for Optimized Drug Delivery in the Treatment of Primary Bone Cancer,” Oncol. Res., vol. 34, no. 7, pp. 9, 2026. https://doi.org/10.32604/or.2026.077723 长按识别二维码阅读英文全文 07 Engineering the Future of ADCs in Non-Small Cell Lung Cancer 非小细胞肺癌ADC药物的未来工程化发展 Mi Rim Kim, Jason Lau, Michele Maffezzoli, Giuseppe Luigi Banna 抗体偶联药物（ADC）正在重塑非小细胞肺癌的治疗格局，但早期ADC药物在靶点选择、连接子稳定性和药物载荷控制方面仍存在明显局限。本文通过综述近年来相关文献和国际肿瘤学会议成果，重点分析了新一代ADC研发中的关键工程化创新，包括人工智能辅助病理分析、液体活检、多组学筛选、生物标志物优化以及定点偶联技术和新型连接子设计等内容。研究指出，双特异性ADC、双载荷ADC以及免疫刺激型ADC正在成为未来发展方向，有望进一步克服耐药并扩大治疗获益人群。引用格式： APA Style Kim, M.R., Lau, J., Maffezzoli, M., Banna, G.L. (2026). Engineering the Future of ADCs in Non-Small Cell Lung Cancer. Oncology Research, 34(7), 2. https://doi.org/10.32604/or.2026.078000 Vancouver Style Kim MR, Lau J, Maffezzoli M, Banna GL. Engineering the Future of ADCs in Non-Small Cell Lung Cancer. Oncol Res. 2026;34(7):2. https://doi.org/10.32604/or.2026.078000 IEEE Style M. R. Kim, J. Lau, M. Maffezzoli, and G. L. Banna, “Engineering the Future of ADCs in Non-Small Cell Lung Cancer,” Oncol. Res., vol. 34, no. 7, pp. 2, 2026. https://doi.org/10.32604/or.2026.078000 长按识别二维码阅读英文全文 08 Prognostic Value of Spatial and Topological Features of Tumor Microenvironment in Classic Hodgkin Lymphoma 经典霍奇金淋巴瘤肿瘤微环境空间拓扑特征的预后价值 Irene Bernal-Florindo, Jose Angel Raposo-Puglia, Felix A. Ruiz, Jose Perez-Requena, Cristian Benavides-de la Fuente, Javier Galan, Maria Jose Berruezo-Salazar, Marcial Garcia-Rojo, Cecilia Fernandez-Ponce, Antonio Santisteban-Espejo 当肿瘤微环境逐渐成为癌症研究的重要焦点时，细胞之间的空间关系开始展现出独特的生物学意义。本文回顾了数字图像分析和计算病理学在经典霍奇金淋巴瘤中的应用进展，重点总结了肿瘤细胞与免疫细胞空间分布特征对患者预后的影响。作者结合单细胞测序、空间转录组学、液体活检和PET/CT影像学等新兴技术，提出了一种基于肿瘤生态系统演化的新型研究框架。研究认为，空间拓扑特征有望成为未来风险分层和个体化治疗的重要生物标志物。引用格式： APA Style Bernal-Florindo, I., Raposo-Puglia, J.A., Ruiz, F.A., Perez-Requena, J., Benavides-de la Fuente, C. et al. (2026). Prognostic Value of Spatial and Topological Features of Tumor Microenvironment in Classic Hodgkin Lymphoma. Oncology Research, 34(7), 3. https://doi.org/10.32604/or.2026.079403 Vancouver Style Bernal-Florindo I, Raposo-Puglia JA, Ruiz FA, Perez-Requena J, Benavides-de la Fuente C, Galan J, et al. Prognostic Value of Spatial and Topological Features of Tumor Microenvironment in Classic Hodgkin Lymphoma. Oncol Res. 2026;34(7):3. https://doi.org/10.32604/or.2026.079403 IEEE Style I. Bernal-Florindo et al., “Prognostic Value of Spatial and Topological Features of Tumor Microenvironment in Classic Hodgkin Lymphoma,” Oncol. Res., vol. 34, no. 7, pp. 3, 2026. https://doi.org/10.32604/or.2026.079403 长按识别二维码阅读英文全文 09 Resveratrol in Oral Squamous Cell Carcinoma: Preclinical Evidence and Translational Opportunities 白藜芦醇在口腔鳞状细胞癌中的抗癌潜力与转化前景 Alessandro Polizzi, Gaetano Isola, Monia Cecati, Nicoletta Bonci, Roberto Campagna, Giovanni Tossetta 天然活性化合物正在成为抗癌药物研发的重要来源。本文通过系统梳理白藜芦醇及其相关衍生物在口腔鳞状细胞癌中的实验研究证据，分析了其抑制细胞增殖、诱导凋亡和铁死亡、阻滞细胞周期以及抑制肿瘤侵袭转移等多重抗肿瘤作用机制。研究还发现，白藜芦醇能够增强化疗、放疗和靶向治疗的疗效并逆转部分耐药机制。然而，受限于生物利用度较低，目前其临床转化仍面临挑战，未来需要更多动物实验和临床研究验证。引用格式： APA Style Polizzi, A., Isola, G., Cecati, M., Bonci, N., Campagna, R. et al. (2026). Resveratrol in Oral Squamous Cell Carcinoma: Preclinical Evidence and Translational Opportunities. Oncology Research, 34(7), 10. https://doi.org/10.32604/or.2026.079642 Vancouver Style Polizzi A, Isola G, Cecati M, Bonci N, Campagna R, Tossetta G. Resveratrol in Oral Squamous Cell Carcinoma: Preclinical Evidence and Translational Opportunities. Oncol Res. 2026;34(7):10. https://doi.org/10.32604/or.2026.079642 IEEE Style A. Polizzi, G. Isola, M. Cecati, N. Bonci, R. Campagna, and G. Tossetta, “Resveratrol in Oral Squamous Cell Carcinoma: Preclinical Evidence and Translational Opportunities,” Oncol. Res., vol. 34, no. 7, pp. 10, 2026. https://doi.org/10.32604/or.2026.079642 长按识别二维码阅读英文全文 10 The Dual Role of Natural Peptides in Cancer Therapy: Anticancer and Immunomodulatory Perspectives 天然肽在癌症治疗中的双重作用：抗肿瘤与免疫调节 Avetis Tsaturyan, Heghine Hakobyan, Kristina Hovsepyan, Anna Mkrtchyan, Tatevik Sargsyan, Raffaele Pastore, Germano Guerra, Giovanni N. Roviello 寻找兼具疗效和安全性的抗癌分子是当前药物研发的重要方向。本文围绕天然肽的抗癌活性和免疫调节功能展开综述，重点分析了其通过抑制肿瘤血管生成、促进肿瘤细胞死亡以及激活T细胞和自然杀伤细胞等机制发挥抗肿瘤作用的研究进展。作者还讨论了天然肽在稳定性、生物利用度和产业化生产方面面临的问题，并提出结合纳米技术、合成肽设计以及个体化治疗策略将成为未来的重要发展趋势。引用格式： APA Style Tsaturyan, A., Hakobyan, H., Hovsepyan, K., Mkrtchyan, A., Sargsyan, T. et al. (2026). The Dual Role of Natural Peptides in Cancer Therapy: Anticancer and Immunomodulatory Perspectives. Oncology Research, 34(7), 11. https://doi.org/10.32604/or.2026.078405 Vancouver Style Tsaturyan A, Hakobyan H, Hovsepyan K, Mkrtchyan A, Sargsyan T, Pastore R, et al. The Dual Role of Natural Peptides in Cancer Therapy: Anticancer and Immunomodulatory Perspectives. Oncol Res. 2026;34(7):11. https://doi.org/10.32604/or.2026.078405 IEEE Style A. Tsaturyan et al., “The Dual Role of Natural Peptides in Cancer Therapy: Anticancer and Immunomodulatory Perspectives,” Oncol. Res., vol. 34, no. 7, pp. 11, 2026. https://doi.org/10.32604/or.2026.078405 长按识别二维码阅读英文全文 11 Clinical Application Progress of Artificial Intelligence in Pancreatic Cancer: From Diagnosis to Immunotherapy 人工智能在胰腺癌中的临床应用进展：从诊断到免疫治疗 Zehao Wei, Xuejian Liu, Zheng Zhang, Yimin Ma, Min Xu 在胰腺癌这一预后极差的恶性肿瘤领域，人工智能正逐渐展现出改变临床实践的潜力。本文系统总结了人工智能在胰腺癌早期筛查、免疫治疗疗效预测和个体化治疗决策中的应用进展，重点介绍了AI结合单细胞测序、多组学分析、肿瘤免疫微环境评估以及纳米药物设计等关键技术。研究认为，人工智能有望帮助破解胰腺癌免疫逃逸和治疗反应差异等难题，为精准免疫治疗提供新的解决方案。引用格式： APA Style Wei, Z., Liu, X., Zhang, Z., Ma, Y., Xu, M. (2026). Clinical Application Progress of Artificial Intelligence in Pancreatic Cancer: From Diagnosis to Immunotherapy. Oncology Research, 34(7), 12. https://doi.org/10.32604/or.2026.078793 Vancouver Style Wei Z, Liu X, Zhang Z, Ma Y, Xu M. Clinical Application Progress of Artificial Intelligence in Pancreatic Cancer: From Diagnosis to Immunotherapy. Oncol Res. 2026;34(7):12. https://doi.org/10.32604/or.2026.078793 IEEE Style Z. Wei, X. Liu, Z. Zhang, Y. Ma, and M. Xu, “Clinical Application Progress of Artificial Intelligence in Pancreatic Cancer: From Diagnosis to Immunotherapy,” Oncol. Res., vol. 34, no. 7, pp. 12, 2026. https://doi.org/10.32604/or.2026.078793 长按识别二维码阅读英文全文 12 Immunometabolic Reprogramming in Hepatocellular Carcinoma Mechanisms, Biomarkers, and Therapeutic Implications 肝细胞癌免疫代谢重编程：机制、生物标志物与治疗启示 Guodong Yu, Weiying Ge, Hongliang Yao, Xuefeng Bai, Jianfei Wu, Yuan Wang, Jiangtao Bai, Yong Cui, Jijing Han 肝细胞癌的发生发展不仅与基因异常有关，更受到代谢紊乱与免疫失衡的共同驱动。本文全面综述了肝细胞癌中免疫代谢重编程的研究进展，重点探讨糖代谢、脂质代谢、氨基酸代谢以及线粒体功能异常如何塑造肿瘤微环境并促进免疫逃逸。通过分析组织样本、液体活检和代谢影像学等来源的免疫代谢生物标志物，作者认为免疫代谢重编程有望成为患者分层管理和精准治疗的重要基础，同时为免疫检查点抑制剂联合治疗策略提供新的理论依据。引用格式： APA Style Yu, G., Ge, W., Yao, H., Bai, X., Wu, J. et al. (2026). Immunometabolic Reprogramming in Hepatocellular Carcinoma Mechanisms, Biomarkers, and Therapeutic Implications. Oncology Research, 34(7), 13. https://doi.org/10.32604/or.2026.080746 Vancouver Style Yu G, Ge W, Yao H, Bai X, Wu J, Wang Y, et al. Immunometabolic Reprogramming in Hepatocellular Carcinoma Mechanisms, Biomarkers, and Therapeutic Implications. Oncol Res. 2026;34(7):13. https://doi.org/10.32604/or.2026.080746 IEEE Style G. Yu et al., “Immunometabolic Reprogramming in Hepatocellular Carcinoma Mechanisms, Biomarkers, and Therapeutic Implications,” Oncol. Res., vol. 34, no. 7, pp. 13, 2026. https://doi.org/10.32604/or.2026.080746 长按识别二维码阅读英文全文 13 OR 期刊简介扫码了解更多期刊信息主编 Enrico Mini University of Florence, ITALY Hailin Tang Sun Yat-Sen University Cancer Center, CHINA Oncology Research是由美国Tech Science Press出版社发行的一本关注癌症治疗的国际英文期刊。重点关注的领域包括开发新型小分子和靶向治疗的临床前和转化研究;药物敏感机制;细胞耐药机制;反应和/或耐药的生物标志物;与癌症治疗相关的新型实验模型系统和技术;药物遗传学和药物基因组学;个性化医学;免疫治疗和临床免疫学;基因治疗等。目前被SCI (Web of Science), Scopus, PubMed等一些世界主要引文数据库收录。平均审稿周期从稿件提交到初审决定：33天从稿件提交到最终录用：95天官方邮箱：oncologyresearch@techscience.com 期刊链接：https://www.techscience.com/journal/or 版权声明本文由Tech Science Press 南京办公室负责编译。中文内容仅供参考，一切内容以英文原版为准。如需转载，请回复“转载”联系小编。点击阅读原文进入官网

2026-06-20

·生物制药合伙人

双抗技术平台——CrossMab

CrossMab 是由罗氏（Roche）开发的、目前双特异性抗体领域中最成熟和应用最广泛的技术平台之一。它通过巧妙的分子设计，有效解决了双抗研发中最大的痛点——轻重链的错配问题。 CrossMab 技术是一种用于开发双特异性抗体（BsAb）的抗体工程技术。主要基于 ‌“Knobs-into-Holes” (KiH)‌ 策略，并在此基础上引入了‌结构域互换‌机制，以确保重链和轻链的正确组装，在抗体的 Fc 区 CH3 结构域进行突变，一条重链引入大分子氨基酸形成“Knob”（凸头），另一条引入小分子氨基酸形成“Hole”（凹坑）。这种空间位阻效应促使两条不同的重链优先形成‌异源二聚体‌，而非同源二聚体，从而解决了重链错配问题。‌‌为了解决轻链与错误重链结合的问题，CrossMab 将其中一条臂的 Fab 区域中的特定结构域进行互换。通过互换，使得同源结构域（如 VH 与 VH、CH1 与 CH1）之间产生排斥力，迫使轻链只能与其原本对应的重链正确结合。‌‌它能够在保留传统 IgG 抗体结构优势（如较长的血清半衰期、Fc 介导的效应功能）的同时，实现单分子对两个不同抗原的特异性结合。该技术极大地提高了双特异性 IgG 抗体的正确装配率和可开发性。 📅 CrossMab 技术发展历程技术诞生： CrossMab 技术由罗氏（Roche）于 2011 年首次提出，是一种用于解决双特异性抗体（BsAb）中轻链错配问题的抗体工程平台，通过在 Fab 区域交换重链（CH1）与轻链（CL）结构域，确保两条不同重链各自与正确轻链配对。早期探索： 2012年由罗氏（Roche/Genentech）开发的首批进入临床试验的基于CrossMab技术的双特异性抗体是 vanucizumab（RG7221），一种靶向VEGF/Ang-2的1+1格式IgG样双抗，该药同时抑制血管内皮生长因子（VEGF）和血管生成素-2（Ang-2），双通路抗血管生成，结构类型属于异二聚体1+1 CrossMab（采用CH1-CL结构域交换 + Knobs-into-Holes重链配对技术）。成熟与广泛应用：在过去十余年中，CrossMab 已发展成为该领域最主流的技术之一。截至 2021 年中，全球已有近 20 种基于 CrossMab 技术的双特异性抗体和融合蛋白进入临床试验阶段，适应症覆盖肿瘤、眼科、自身免疫病等多个领域。药物名称研发编号靶点技术格式适应症临床阶段开发状态 Vanucizumab RG7221 VEGF/Ang-2 1+1 CrossMab CH1-CL 转移性结直肠癌 Ⅱ期临床开发已终止（Ⅱ期未击败贝伐珠单抗） RG7386 - FAP/DR5 2+2 CrossMab CH1-CL 实体瘤 Ⅰ期完成Ⅰ期后因管线优先级调整终止 PD1-TIM3 RG7769 PD-1/TIM-3 1+1 CrossMab 实体瘤 Ⅰ/Ⅱ期正在进行中 PD1-LAG3 RG6139 PD-1/LAG-3 1+1 CrossMab 实体瘤 Ⅰ/Ⅱ期正在进行中 Cibisatamab (CEA-TCB) RG7802 CEA/CD3ε 2+1 CrossMab CH1-CL CEA阳性实体瘤 Ⅰb期联合PD-L1抗体正在进行评估 Glofitamab RG6026 CD20/CD3ε 2+1 CrossMab VH-VL± 复发难治B细胞非霍奇金淋巴瘤 Ⅲ期 2023年已在加拿大获批上市，FDA已接受上市申请 Faricimab RG7716 Ang-2/VEGF 1+1 CrossMab CH1-CL 湿性黄斑变性、糖尿病黄斑水肿完成Ⅲ期已获批上市 RG6123 - CEACAM5/CD3ε 2+1 CrossMab VH-VL± CEACAM5阳性实体瘤早期已终止开发表1：基于CrossMab技术的主要双抗药物（根据公开资料整理）商业化成功：近年来，多款基于 CrossMab 平台的药物成功获批上市，标志着该技术平台的全面成熟。项目详情通用名法瑞西单抗（faricimab-svoa）商品名 Vabysmo 研发/生产企业罗氏旗下基因泰克（Genentech）技术类型人源化双特异性抗体，采用1+1 CrossMab CH1-CL技术靶点同时靶向血管内皮生长因子A（VEGF-A）、血管生成素-2（Ang-2）首次获批时间 2022年1月28日（FDA）批准国家/地区已在近100个国家和地区获批，2024年10月中国获批新适应症表2：全球首个基于CrossMab技术获批上市的双抗‌Faricimab 图1：Faricimab作用机制示意图（来源网络） ⚙️ CrossMab技术原理传统 IgG 样双抗在制备时，两条不同的重链和两条不同的轻链容易发生随机组合，导致产生大量无效的同源二聚体或错配抗体。CrossMab 技术通过“双重保险”机制完美解决了这一难题： 1. 解决重链错配：在抗体的 Fc 区采用经典的“Knobs-into-Holes (KiH，旋钮入孔)”技术。通过基因工程突变，在一条重链的 CH3 结构域引入较大的氨基酸（凸起/Knob），在另一条重链引入较小的氨基酸（孔洞/Hole），利用空间位阻效应强制两条不同的重链正确配对。 2. 解决轻链错配：这是 CrossMab 的核心创新。它将其中一臂 Fab 区域的特定结构域进行“交叉互换”（Crossover）。通过这种交换，使得该臂的重链只能与它原本对应的轻链结合，从空间结构上杜绝了与其他轻链错误配对的可能。 ✨ CrossMab技术主要特点极高的纯度与装配率：能够强制实现正确的轻重链配对，显著减少副产物，目标双抗的纯度极高。保留 IgG 优良特性：具有与传统单抗相似的结构，保留了 Fc 段介导的 ADCC/CDC 等效应功能，且拥有较长的血清半衰期，给药频率低。良好的可开发性：表达产量高，理化性质稳定，生产工艺与常规单抗兼容，易于大规模工业化生产。高度的灵活性与通用性：可以基于任何现有的抗体对进行改造，无需寻找“共同轻链”，且能衍生出多种复杂的分子形式。 🧬 CrossMab技术设计方法 1. CrossMab Fab：交换整个 Fab 区域（即 VH-CH1 与 VL-CL 互换）。这种设计会产生一定的非功能性副产物。 2. CrossMab VH-VL：仅交换 Fab 区域中的可变区（VH 与 VL 互换）。这种设计可能会产生类似 Bence-Jones 蛋白的副产物。 3. CrossMab CH1-CL：仅交换 Fab 区域中的恒定区（CH1 与 CL 互换）。理论预测和实际数据均表明，这种设计的副产物最少，纯度和稳定性最佳，是目前最优选的设计方案。此外，CrossMab 平台还能衍生出多种多特异性分子格式，如三价（2+1）、四价（2+2）双抗，甚至三特异性、四特异性抗体。参考资料： 1.Ten years in the making: application of CrossMab technology for the development of therapeutic bispecific antibodies and antibody fusion proteins. MAbs. Jan-Dec 2021;13(1):1967714. 2.Ten years in the making: application of CrossMab technology for the development of therapeutic bispecific antibodies and antibody fusion proteins. MAbs.2021 Jan-Dec;13(1):1967714. doi: 10.1080/19420862.2021.1967714. 3.4.Roche YTD September 2023 results, Basel, 19 October 2023 4.封面图来源网络。公众号已建立“生物药工艺开发技术交流”微信群，添加小编微信514099167 加入，加微信时备注姓名-单位-岗位，非生物制药行业人员勿扰。生物制药合伙人扫码关注我们 ID：zpt_Partner W：514099167 分享，点赞，在看！为生物制药人三连击！

2026-06-05

·中科普瑞科研服务

JZGENE DRUG-seq 高通量转录组测序服务

01 服务简介 JZGENE DRUG-seq 是中科普瑞-上海鲸舟基因实验室推出的免 RNA 提取、超高通量 3' 端高通量批量转录组测序服务，专为大规模药物筛选表达谱开发，依托上海鲸舟基因CAP实验室落地服务，面向药企与科研院所提供低成本、高灵敏度、超高样本通量的药物诱导基因表达谱检测方案。核心技术优势零 RNA 提取步骤：省去传统 RNA 抽提流程，避免核酸损耗，细胞直接冻存送样即可建库，大幅减少样本损失与人工成本；兼容3000细胞~5000细胞/孔检测。超高样本通量：适配 96/384 孔细胞培养板高通量筛选。高基因检出效率：单样本 1M reads测序稳定检出13000 + 基因，推荐3M reads / 样本可检出超 18000 个基因，优于常规全长度 RNA-seq 测序深度性价比。批次稳定性优异：跨批次数据重复性好，可支撑大批量化合物平行筛选、药物组合转录组聚类分析。成本与周期优势：标准化流水线 + 规模化测序平台，市面性价比突出、交付周期可控。技术属性：3' 端靶向 RNA 测序，区别于全长转录组，用更低测序量实现精准基因定量。 02 应用领域新药化合物筛选（工业端核心场景）大规模小分子 / 候选药物高通量初筛，依托药物扰动后的转录组特征实现化合物聚类、活性分类，快速筛选先导化合物；支持单药、复方联用药物转录图谱对比（UMAP 聚类分析区分单药 / 联用 / 空白对照组转录特征）。 2.药物作用机理（MoA）研究解析候选药物调控通路、作用靶点，结合基因差异表达数据阐明分子机制，已用于前列腺癌、结直肠癌靶向药（Cibisatamab）机理发表研究。 3.新一代药物毒理评价基于细胞转录组变化做早期体外毒性筛查，替代部分动物预实验，提升新药安全性早期评估效率，适配 2D 细胞、干细胞类器官、肿瘤球 Spheroid 三类体外模型。 4. 基础科研肿瘤机制、原代细胞生物学、基因调控等学术课题，已在多个经典细胞系完成样本验证。 03 收样指南（一）样本规格与细胞用量（二）两种送样形式：细胞裂解液 / 冻存细胞 DRUG-seq (lysate，裂解液样本,主流方案)：细胞裂解后收集裂解物分装送样，参照专属裂解液送样规范。 DRUG-seq (frozen，冻存细胞运输) 客户：药物处理细胞→PBS 清洗去除培养基→孔板密封、冷冻保存。按照以上任一方式处理后，填写样品提交单，冷链寄送 96/384 冻存板至上海鲸舟基因实验室（地址：上海市浦东新区康新公路3399弄26号楼7楼）。 04 交付结果 1. 原始测序数据 FASTQ 原始测序文件（全样本下机原始 reads）。 2. 定量核心文件标准化基因表达计数矩阵（gene count matrix），可直接导入 R、Python、GraphPad 等软件开展下游差异基因、聚类、富集分析。 3. 质控文件文库质控报告、测序质控 QC 文件（浓度、片段分布、基因组比对率统计）。 4. 项目分析报告标准化分析报告：包含样本质控汇总、基因组比对统计、整体表达概况。生信增值说明：标准服务含参考基因组比对 + 基础生信分析；如需个性化深度分析（药物聚类、GSEA 富集、差异基因筛选）可额外定制。项目启动方式预约鲸舟基因客户经理线上沟通：和产品线技术专家沟通项目设计、样本量、测序参数；提交实验方案表单：填写项目需求，JZGENE评估方案并报价；可选前置小预实验（Pilot）：小规模样本测试实验条件，优化后再开展全规模筛选。公司简介 Sinotech Genomics 上海鲸舟基因科技有限公司始创于 2017 年，是拥有CAP 实验室认证、聚焦精准医学领域的高新技术服务商，面向各级医疗机构、科研院所、生物医药企业一站式输出专业化精准医学整体解决方案。公司深耕重大疾病精准诊疗与前沿组学科研服务，主营业务聚焦肿瘤全周期管理，覆盖患病风险预警、早期筛查、个体化用药指导、预后疗效评估；并深耕 DNA 甲基化标志物转化、病原微生物及耐药基因测序、精准蛋白组标志物挖掘等特色技术方向。依托单细胞测序、Olink 靶向蛋白组、全基因组 / 转录组测序等多组学一体化技术平台与自研生物信息算法体系，公司深度布局新药研发 CRO 服务，贯穿靶点挖掘、候选药筛选、临床前药理验证、伴随诊断试剂开发全链条，可完成从生物标志物筛选、实验室验证到临床落地转化的全流程技术交付。企业资质荣誉积淀丰厚：2019 年获评高新技术企业，2020 年认定为浦东新区企业研发机构，2021 年入选上海市专精特新中小企业，2024 年承建上海市商委服务贸易类「新一代生物标志物检测与分析公共服务平台」，2026 年实验室顺利取得 CAP 国际权威认证，质控与技术能力接轨国际标准。质量体系资质往期推荐: DRUG-seq：高通量转录组测序技术驱动药物筛选范式变革 DRUG-seq技术优势及其在AI驱动药物发现中的应用价值

100 项与 Cibisatamab 相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
D11489	-	-	-

研发状态

10 条进展最快的记录,

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
转移性非小细胞肺癌	临床2期	美国	Hoffmann-La Roche, Inc.	2017-12-27
转移性非小细胞肺癌	临床2期	澳大利亚	Hoffmann-La Roche, Inc.	2017-12-27
转移性非小细胞肺癌	临床2期	法国	Hoffmann-La Roche, Inc.	2017-12-27
转移性非小细胞肺癌	临床2期	以色列	Hoffmann-La Roche, Inc.	2017-12-27
转移性非小细胞肺癌	临床2期	韩国	Hoffmann-La Roche, Inc.	2017-12-27
转移性非小细胞肺癌	临床2期	西班牙	Hoffmann-La Roche, Inc.	2017-12-27
转移性非小细胞肺癌	临床2期	英国	Hoffmann-La Roche, Inc.	2017-12-27
转移性结直肠癌	临床1期	美国	Hoffmann-La Roche, Inc.	2019-05-07
转移性结直肠癌	临床1期	丹麦	Hoffmann-La Roche, Inc.	2019-05-07
转移性结直肠癌	临床1期	法国	Hoffmann-La Roche, Inc.	2019-05-07

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT04826003 (BP42675, AACR2026)	临床1期	转移性微卫星稳定结直肠癌三线 microsatellite-stable	51	Cibisatamab + FAP-4-1BBL	鹽鏇壓夢艱顧遞糧製鬱(醖鏇鹽獵衊繭壓簾壓築) = 艱鹽鏇鑰鬱衊鹽顧襯醖艱襯膚衊鹹醖獵壓觸顧 (鏇蓋壓憲繭夢壓繭網蓋 ) 更多	积极	2026-04-20
NCT04826003 (Pubmed \| Nat Med)	临床1期	转移性微卫星稳定结直肠癌三线 microsatellite-stable	52	Cibisatamab + FAP-4-1BBL (Microsatellite-stable metastatic colorectal cancer + Progressed after two or more prior therapies)	鹹繭遞襯鹽獵簾窪鑰糧(觸網鏇顧淵鏇糧淵範鏇) = 淵鏇築遞積構憲齋夢築衊範醖憲獵繭鏇簾膚鏇 (鏇網艱夢繭衊膚獵淵願 ) 更多	积极	2026-04-20
NCT02324257 (ESMO2017) 人工标引	临床1期	结肠转移性腺癌 CEA Positive	45	RG7802 (CRC and At doses ≥ 60 mg)	製憲齋餘蓋襯築願醖艱(觸壓衊蓋鬱鬱製艱蓋選) = In S1 (out of 59 pts > 40 mg), IRRs (24%) and diarrhea (7%). 願獵壓鏇鑰衊簾鬱鑰憲 (醖獵繭衊顧願衊簾鏇選 ) 更多	积极	2017-09-11
				Atezolizumab+RG7802 (CRC and At doses ≥ 60 mg)
NCT02324257 \| NCT02650713 (ASCO2017)	临床1期	转移性结直肠癌	-	CEA-CD3 TCB	襯鑰蓋艱憲膚蓋觸選積(廠壓膚構糧餘餘廠醖糧) = 蓋齋蓋齋選糧顧範艱願繭構醖鬱壓獵願選齋製 (齋構廠構糧淵醖觸選簾 ) 更多	-	2017-05-30
				Atezolizumab	襯鑰蓋艱憲膚蓋觸選積(廠壓膚構糧餘餘廠醖糧) = 鏇淵鑰鹹積獵範範願衊繭構醖鬱壓獵願選齋製 (齋構廠構糧淵醖觸選簾 )